Glenmark Generics Launches Trandolapril Tablets
Posted on: Tuesday, 24 June 2008, 02:30 CDT
Glenmark Generics, a subsidiary of Glenmark Pharmaceuticals, has received ANDA approval from the FDA for Trandolapril tablets USP 1mg, 2mg and 4mg and will immediately commence marketing and distribution of these products in the US market.
Glenmark's Trandolapril is an angiotensin converting enzyme inhibitor used to treat high blood pressure and is the generic equivalent of Mavik tablets marketed by Abbott Laboratories.
This recent approval coupled with the three abbreviated new drug application approvals received from the FDA in May 2008 for Mometasone cream USP 0.1%, Mometasone ointment USP 0.1% and Metformin tablets USP 500mg, 850mg, 1000mg brings Glenmark's current portfolio to 33 generic products authorized for distribution in the US market.
Source: Datamonitor
Related Articles
- Salix Pharmaceuticals Receives Approvable Letter From FDA for Balsalazide Tablet
- Salix Pharmaceuticals Announces Submission of Granulated Mesalamine New Drug Application
- Salix Pharmaceuticals Licenses OSMOPREP(TM) To Mayoly-Spindler in France
- Salix Pharmaceuticals Acquires Patent-Protected Metoclopramide-Zydis(R)
- Rifaximin Demonstrates Statistically Significant Improvement in Co-Primary Endpoints in Treatment of Diarrhea-Associated Irritable Bowel Syndrome in Phase IIb Study
- Salix Pharmaceuticals Announces Co-Promotion Agreement for Balsalazide
- Salix Pharmaceuticals Reports 2Q2007 Results
- Salix Pharmaceuticals Announces Submission of Balsalazide Tablet New Drug Application
- Three Rivers Pharmaceuticals Announces FDA Final Approval of Ribasphere(R) (Ribavirin, USP) Tablets 600mg, 400mg and 200mg for the Treatment of Chronic Hepatitis C
- Three Rivers Pharmaceuticals Announces FDA Tentative Approval of Ribasphere(R) (Ribavirin, USP) Tablets for the Treatment of Chronic Hepatitis C
User Comments (0)
RSS Feeds